Crispr Therapeutics AG (NASDAQ:CRSP) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $74.00 and last traded at $72.61, with a volume of 447290 shares. The stock had previously closed at $73.13.

CRSP has been the topic of a number of recent analyst reports. Piper Jaffray Companies reaffirmed a “buy” rating and set a $104.00 price target on shares of Crispr Therapeutics in a research report on Tuesday, November 26th. William Blair raised Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Tuesday, November 19th. Roth Capital raised their price objective on Crispr Therapeutics from $65.00 to $100.00 in a research report on Tuesday, November 19th. Goldman Sachs Group boosted their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Finally, Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $69.54.

The stock’s fifty day simple moving average is $54.12 and its 200-day simple moving average is $47.22. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The firm has a market cap of $3.95 billion, a PE ratio of -20.56 and a beta of 3.30.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Analysts expect that Crispr Therapeutics AG will post 0.65 earnings per share for the current year.

In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total transaction of $390,000.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $390,000. The disclosure for this sale can be found here. Insiders sold a total of 56,118 shares of company stock valued at $3,620,760 in the last 90 days. 21.40% of the stock is currently owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Nikko Asset Management Americas Inc. increased its stake in shares of Crispr Therapeutics by 324.3% in the second quarter. Nikko Asset Management Americas Inc. now owns 1,871,408 shares of the company’s stock worth $88,143,000 after acquiring an additional 1,430,364 shares during the period. ARK Investment Management LLC boosted its holdings in Crispr Therapeutics by 34.7% in the second quarter. ARK Investment Management LLC now owns 2,724,349 shares of the company’s stock valued at $128,317,000 after purchasing an additional 701,332 shares during the last quarter. Orbimed Advisors LLC acquired a new stake in Crispr Therapeutics during the 3rd quarter worth about $21,167,000. Price T Rowe Associates Inc. MD grew its position in Crispr Therapeutics by 19.6% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock worth $34,801,000 after purchasing an additional 121,176 shares during the period. Finally, Wells Fargo & Company MN grew its position in Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after purchasing an additional 116,540 shares during the period. 49.81% of the stock is currently owned by institutional investors and hedge funds.

Crispr Therapeutics Company Profile (NASDAQ:CRSP)

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: What are gap-down stocks?

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link